This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Browse our events, training, articles and people by topicclose

Popular sectors

A - Z

Browse Topicsappsclose
search

Peptides & Oligonucleotides

Accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.

Events

Showing 4 of 7 eventsView all events

AsiaTIDES: Oligonucleotide & Peptide Therapeutics

February 24-26, 2020, Kyoto, Japan

THE ONLY EVENT IN ASIA BRINGING TOGETHER SCIENCE, TECHNOLOGIES AND PARTNERS TO ACCELERATE OLIGONUCLEOTIDE AND PEPTIDE MOLECULES TO MARKET

TIDES: Oligonucleotide and Peptide Therapeutics

May 11-14, 2020, Boston, MA

THE WORLD’S LARGEST MEETING TO ACCELERATE OLIGONUCLEOTIDE AND PEPTIDE PRODUCTS FROM EARLY DISCOVERY TO LATE-STAGE DEVELOPMENT & COMMERCIALIZATION

Next Generation CAR & T Cell Therapies

June 22-24, 2020, San Francisco, CA

CAR and T Cell Therapies: Pioneering point of care with innovative manufacturing and commercialization strategies

Next Generation Protein Therapeutics Summit

June 22-24, 2020, San Francisco, CA

Looking beyond antibodies to transform promising proteins into next generation medicine

Articles & Video

Showing 9 of 29 articles & videoView all articles & video
Featured
Antibody Engineering

Life Sciences in 2020: Predictions from industry insiders

Industry insiders predict how life sciences will change in 2020 in emerging therapies, clinical trials, regulations and agriculture.

Premium
Peptides

The future of peptide vaccines and personalized peptide therapies - WHITEPAPER

This whitepaper explores the exciting potential future of peptide vaccines and personalized peptide therapies.

Premiumget_app
Peptides and Oligonucleotides

Regulatory challenges and strategies for oligonucleotide, peptide and mRNA therapeutics - WHITEPAPER

We explore the regulatory challenges and successful approval strategies for oligonucleotide, peptide and mRNA therapeutics.

Oligonucleotides

What is an oligonucleotide?

What is an oligonucleotide? Discover the different oligo classes and the future of oligonucleotide therapies.

Peptides and Oligonucleotides

Drug delivery trends in oligo, peptide, mRNA and CRISPR therapeutics

Peptides

What are peptides?

Peptides and Oligonucleotides

How oligonucleotide, peptide, CRISPR and mRNA companies are using collaboration to move forward

Premium
CRISPR

REPORT: State of Oligo, Peptide, mRNA and CRISPR Therapeutics 2019

Premium
Cell and gene therapy

CMC approaches to accelerate peptide, oligonucleotides and mRNA therapeutics development - WHITEPAPER

SPONSORSHIP & EXHIBITION OPPORTUNITIES

There are many ways for your organisation to engage a qualified audience of 40,000+ TIDES executives and scientists, including 2,000+ annual attendees gathered across the globe! Share your strategy and plans so we can help you identify the best opportunities to reach your objectives. Our team will collaborate with you to develop a bespoke program tailored to your unique needs.

To find out more, contact Michael Dunnet, Head of Portfolio Sales:
michael.dunnet@informa.com | +1 (857) 504-6732

All opportunities can be customised to align with your needs and budget. Examples may include:

  • Exhibition space
  • Speaking slots and onsite video interviews
  • High-impact branding and messaging
  • Private/public hosted events (lunches, breakfasts, and receptions)
  • Custom digital campaigns
DOWNLOAD 2020 SPONSOR PROSPECTUS

Copyright © 2020 Informa Connect, a trading name of IIR Limited. IIR Limited registered in England & Wales with number 01835199, registered office 5 Howick Place, London, SW1P 1WG.